NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

TSX · Biotechnology · CAD

Microbix Biosystems Inc. (MBX.TO) Stock Analysis

Microbix Biosystems Inc. (MBX.TO) is a Biotechnology stock listed on TSX and quoted in Canadian Dollar.

MBX.TO

CA$0.30

+CA$0.01 (+3.45%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare MBX.TO with… →

MBX.TO Key Statistics

As of Sep 4, 2026
Trading
Open
CA$0.29
Previous Close
CA$0.29
Day's Range
0.29–0.30
52-Week Range
0.21–0.33
Volume
15.50K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.57
Valuation
Market Cap
CA$40.41M
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
14.75
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
2.62
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.04
Financials (FY)
Profit marginThe share of revenue left as profit after all costs and taxes.
−31.72%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
136.97M
1-Year Return
+30.43%
Dividend and dates
Avg Volume
27.81K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

MBX.TO Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+30.43%
2025−43.90%
2024+5.13%
2023−4.88%
2022−50.60%
2021+93.02%
2020+72.00%
2019+4.17%
2018−22.58%
2017+19.23%
2016 (partial year)−3.70%

As of September 4, 2026.

MBX.TO Valuation vs Biotechnology Median

Median of 656 stocks
MetricMBX.TOBiotechnology medianvs median
P/S ratio2.6215.260.2x the median
Profit margin−31.72%0.00%31.7 pts below

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

Microbix Biosystems Inc. (MBX.TO) carries a market capitalisation of CA$40.41M. The company sits in the Healthcare sector, in the Biotechnology industry.

The most recent close on file for MBX.TO is CA$0.30, dated September 4, 2026. That is +CA$0.01 (+3.45%) against the previous close. Over the past 52 weeks the price has ranged from CA$0.21 to CA$0.33. The latest close sits 42.86% above that 52-week low.

Financial Health

Trailing twelve-month revenue on file is CA$15.40M. Profit margin runs at −31.72%. That is 31.7 percentage points below the Biotechnology median of 0%. Trailing earnings per share are −0.04.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The forward P/E on file is 14.75. The price-to-sales ratio is 2.62. On price-to-sales that is 0.2 times the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

The reported beta is 0.57. Daily returns over the trailing 10 years annualize to a volatility of 61.66%. The trailing one-year price return is +30.43%. Across 10 years the annualized return works out at +1.06%.

Growth & Income

The record shows no dividend for MBX.TO.

So far in 2026 the price is +30.43%. Across the complete calendar years on file, 2021 returned +93.02% and 2022 returned −50.60%. Of the 9 complete calendar years on file, 5 finished higher.

Peer Comparison

Microbix Biosystems Inc. (MBX.TO) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Microbix Biosystems Inc. MBX.TO CA$40.41M —
Vertex Pharmaceuticals Incorporated VRTX CA$138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN CA$85.22B 20.5
argenx SE ARGX CA$64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Microbix Biosystems Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Microbix Biosystems Inc.

Microbix Biosystems Inc., a life science company, develops and commercializes proprietary biological and technological solutions for human health and wellbeing in North America, Europe, and internationally. The company manufactures a wide range of critical biological materials and medical devices for the global diagnostics industry, notably test ingredients (Antigen business) used in immunoassays, quality assessment, and diagnostic-test products, such as test-controls under the QAPs brand; viral transport medium for enabling the collection of patient samples to test for pathogens including virus causing the COVID-19 disease under the DxTM brand; Kinlytic, a biologic thrombolytic drug used to treat blood clots; and antigen products. It also provides customer vial filling services. Microbix Biosystems Inc. was founded in 1988 and is headquartered in Mississauga, Canada.

Visit website →